< Back to previous page
Researcher
Dominique Schols
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Responsible
From1 Jan 2014 → Today - Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 29
- Validation of CCR8 agonism as therapeutic strategy for treatment of (auto-)inflammationFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- Real-time, label-free analysis of extracellular vesicles and their proteins using surface plasmon resonance technologyFrom29 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The viral G protein-coupled receptor ORF74: Expanding the toolbox to better understand receptor signaling, function and pharmacologyFrom22 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Elucidation of the mechanism of action of novel HTLV-1 inhibitors: a step-by-step approachFrom21 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development and preclinical evaluation of diagnostic and therapeutic radiopharmaceuticals targeting CXCR4From10 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development of allosteric intracellular modulators attenuating chemokine receptor CCR5 signallingFrom1 May 2021 → TodayFunding: BOF - doctoral mandates
- A novel class of reversible Exportin-1 inhibitors for cancer therapyFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- Design and synthesis of next-generation C-C chemokine receptor type 5 antagonists.From28 Jul 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Intravital microscopy platform for infectious and inflammatory diseasesFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Discovery of CCR7 small molecule inhibitors by virtual screening andhit-to-lead optimization.From1 Oct 2019 → 30 Sep 2021Funding: BOF - projects
Publications
311 - 320 of 371
- Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor(2011)
Authors: Dominique Schols
Pages: 167 - 176 - HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay(2011)
Authors: Dominique Schols
Pages: 231 - 243 - Synthesis of novel CADA analog prodrugs designed as down-modulators of the CD4 receptor(2011)
Authors: Emily Scarbrough, Kurt Vermeire, Dominique Schols, Thomas Bell
Pages: A75 - A76 - Effect of Molecular Symmetry on Potency in Novel Down-Modulators of the CD4 Receptor(2011)
Authors: Thomas W Bell, Violeta G Demillo, Florian Goulinet-Mateo, Rameez Ali, Nicholas C Pflug, Chiraphorn Khan, Kurt Vermeire, Dominique Schols
Pages: A68 - A68 - CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection(2011)
Authors: Mieke Gouwy, Sofie Struyf, Christophe Vanormelingen, Dominique Schols, Jo Van Damme
Pages: 963 - 973 - Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs)(2011)
Authors: Geoffrey Férir, Kurt Vermeire, Dana Huskens, Jan Balzarini, Dominique Schols
Pages: 200 - 204 - Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication(2011)
Authors: Dana Huskens, Dominique Schols
Pages: 2450 - 2455 - Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide(2011)
Authors: Christophe Pannecouque, Dominique Schols, Jan Balzarini
Pages: 1587 - 1598 - Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication(2011)
Authors: Dana Huskens, Dominique Schols
Pages: 1414 - 1418 - Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity(2011)
Authors: Bart Hoorelbeke, Dominique Schols, Kristel Van Laethem, Jan Balzarini
Pages: 10
Patents
1 - 6 of 6
- Isoquinoline and pyridine based cxcr4 antagonists (Inventor)
- Prodrugs of nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)